within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FX14_PolatuzumabVedotin;

model PolatuzumabVedotin
  extends Pharmacolibrary.Drugs.ATC.L.L01FX14
  // parameters inherited from base class, duplicate, uncomment and change if necesarry
  /*
  
    weight         = 70,
    F              = 1,
    Cl             = 1.0416666666666667e-08,
    adminDuration  = 600,
    adminMass      = 1.8 / 1000000,
    adminCount     = 1,
    Vd             = 0.00315,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0025,
    k12             = 9.49074074074074e-09,
    k21             = 9.49074074074074e-09
      
  */
  ;

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>PolatuzumabVedotin</td></tr><tr><td>ATC code:</td><td>L01FX14</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>1.8</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>3.15</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.9</td><td>L/day</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b, used for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It is approved for medical use in several regions including the US and EU.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics in adult patients with relapsed/refractory B-cell lymphoma. Parameters are for acMMAE (antibody-conjugated monomethyl auristatin E component) in predominantly older adults (~61 years, both sexes).</p><h4>References</h4><ol><li><p>Shemesh, CS, et al., &amp; Lu, D (2020). Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma. <i>Cancer chemotherapy and pharmacology</i> 85(5) 831â€“842. DOI:<a href=\"https://doi.org/10.1007/s00280-020-04054-8\">10.1007/s00280-020-04054-8</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32222808/\">https://pubmed.ncbi.nlm.nih.gov/32222808</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end PolatuzumabVedotin;
